

Joint BSHT, NEQAS & AiP Annual Scientific Meeting

12-13 November : London

Oral presentations Thursday

O1	11:30	Richard	Starke	VON WILLEBRAND FACTOR (VWF) DEFICIENCY CORRELATES WITH INCREASED ANGIOPOIETIN (ANG)-2 SYNTHESIS AND ANGIOGENESIS
O2	11:45	Tom	McKinnon	THE ROLE OF VON WILLEBRAND FACTOR IN FIBRIN CLOT FORMATION AND LYSIS
O3	12:00	Christopher	Lynch	INTRADOMAIN HYDROPHOBIC INTERACTION OF N1574-GLCNAC GLYCAN STABILISES THE VWF A2 DOMAIN AND PREVENTS ADAMTS13 PROTEOLYSIS
O4	12:15	Marta	de Freitas	THE SPACER-CUB DOMAIN INTERACTION OF ADAMTS13
O5	12:30	Tom	McKinnon	FACTORS AFFECTING THE CLEAVAGE OF VON WILLEBRAND FACTOR BY ADAMTS13 UNDER SHEAR STRESS
P6	12:45	Kieron	South	A NOVEL ROLE OF ADAMTS13 IN THE REGULATION OF THROMBUS FORMATION AND STABILITY

Oral presentations Friday

O7	9:00	Samantha	Moore	OPPOSING ROLES OF GLYCOGEN SYNTHASE KINASE-3 PHOSPHORYLATION IN PAR AND GPVI MEDIATED PLATELET FUNCTION AND THROMBOSIS
O8	9:15	Katherine	Bridge	INHIBITION OF THROMBIN-ACTIVATABLE FIBRINOLYSIS INHIBITOR AFFECTS ANEURYSM DEVELOPMENT BUT NOT PROGRESSION IN THE ANGIOTENSIN II MODEL OF AAA
O9	9:30	Isabelle	Salles	ENDOTHELIAL BAMBI (BMP AND ACTIVIN MEMBRANE BOUND INHIBITOR) IS IMPORTANT FOR FIBRIN GENERATION AND THROMBUS STABILITY
O10	9:45	Anne	Goodeve	NEXT GENERATION DNA SEQUENCING PANEL FOR HAEMOSTATIC AND PLATELET DISORDERS IN ROUTINE DIAGNOSTIC SERVICE
O11	10:00	Mohammad	Jalal	STATINS ATTENUATE PRENYLATION OF RAB27B THEREBY IMPEDING RELEASE OF DENSE GRANULES FROM ACTIVATED PLATELETS
O12	10:45	Paraskevi	Untiveros	HAEMATOCRIT MODULATES CLOT FORMATION AND STABILITY AGAINST DEGRADATION

Scientists in training Symposium Friday

O13	13:30	Robert	Dinsdale	NEUTROPHIL EXTRACELLULAR TRAP (NET) FORMATION IN PATIENTS WITH BURN INJURY
O14	13:45	Joanne	Mitchell	LIPID RAFTS AND TRANSGLUTAMINASE ACTIVITY MEDIATE TRANSLOCATION OF FACTOR XIII-A FROM THE ACTIVATED PLATELET MEMBRANE TO BOUND FIBRIN

015	14:00	Mitchell	Geer	TYROSINE PHOSPHORYLATION OF THE ITIM-CONTAINING RECEPTOR G6B-B IS ESSENTIAL FOR PLATELET HOMEOSTASIS
016	14:15	Gael	Morrow	PLASMINOGEN ACTIVATOR INHIBITOR 1 IS RETAINED ON THE SURFACE OF ACTIVATED PLATELETS VIA A FIBRIN SPECIFIC MECHANISM
017	14:30	Jane	Norman	A F2RL3 VARIANT PREDICTING A Tyr157Cys SUBSTITUTION IN PROTEASE-ACTIVATED RECEPTOR 4 IS ASSOCIATED WITH REDUCED RECEPTOR FUNCTION IN PLATELETS
018	14:45	Simon	Webster	HIGH RESOLUTION MICROSCOPIC CHARACTERISATION OF VWF BIOSYNTHESIS, STORAGE AND SECRETION IN TYPE 1 VWD PATIENTS WITH LARGE IN-FRAME VWF DELETIONS

Poster presentations

	Presenting author		Abstract title
P01	Alexandra	Agapidou	THE EFFECT OF DDAVP ON THROMBIN GENERATION IN PATIENTS WITH MILD HAEMOPHILIA A.
P02	Philip	Bath	PLATELET FUNCTION IN PATIENTS WITH ACUTE STROKE OR TIA ADMITTED TO THE TARDIS STUDY ALREADY RECEIVING TREATMENT WITH ANTIPLATELET AGENTS
P03	Georgina	Naylor	COAGULATION TESTS IN AN ATYPICAL OVERDOSE OF RIVAROXABAN
P04	Kathryn	Boyd	THE INTRODUCTION OF DIRECT ORAL ANTICOAGULANTS (DOACS) TO THE SOUTHERN TRUST
P05	Karen	Breen	EARLY OUTCOMES FOLLOWING ENDOLUMINAL DEEP VENOUS STENTING USING DEDICATED VENOUS STENTS
P06	Kate	Burley	RESTORATION OF THROMBIN GENERATION IN INHERITED THROMBOMODULIN-ASSOCIATED BLEEDING DISORDER
P07	Pavel	Chudakou	SINGLE CENTRE EXPERIENCE OF MANAGEMENT OF PATIENTS WITH ACQUIRED HAEMOPHILIA (AH) AND ACQUIRED VON WILLEBRAND DISEASE (AVWD).
P08	Sally	Cox Morton	SAMPLE TRANSPORT ORIENTATION AFFECTS MICROPARTICLE RELEASE AND SPECIALIST HAEMOSTASIS RESULTS.
P09	David	Cunningham	USE OF OCTAPLEX AT A SOUTH THAMES DISTRICT GENERAL HOSPITAL: A CLOSED LOOP CLINICAL AUDIT
P10	Andria	Demosthenous	CHARACTERISATION OF A NOVEL VON WILLEBRAND FACTOR VARIANT CAUSING TYPE 2A VON WILLEBRAND DISEASE
P11	Bradley	Dickinson	SIEMENS XPRECIA STRIDETM VALIDATION STUDY USING THE ACL TOPÒ WITH HEMOSILÒ RECOMBIPLASTIN REAGENT AND THE ROCHE COAGUCHEKÒ XS PRO
P12	Carrie	Dinning	WHY IS SCREENING BY THE CURRENT STANDARD OF CARE FOR DVT OF LIMITED UTILITY IN SUSPECTED UPPER LIMB DEEP VENOUS THROMBOSIS?
P13	Irina	Earnshaw	LUPUS ANTICOAGULANT TESTING IN CENTRAL MANCHESTER FOUNDATION TRUST – WHAT CAN BE IMPROVED?
P14	Emma	Fosbury	REVERSAL OF THE HEPARIN EFFECT WITH PROTHROMBIN COMPLEX CONCENTRATE – AN IN VITRO STUDY USING THE THROMBIN GENERATION ASSAY
P15	Emma	Fosbury	COMPARISON OF THE EFFECT OF FRESH FROZEN PLASMA PRE-AND POST-TRANSFUSION IN ITU PATIENTS ON ROUTINE AND GLOBAL HAEMOSTATIC ASSAYS
P16	Rebekah	Fretwell	ADAMTS-13 STABLE IN CITRATED WHOLE BLOOD FOR 48 HOURS

P17	Dan	Hampshire	FUNCTIONAL CHARACTERISATION OF A NOVEL SPLICE MUTATION, C.7887+2T>A, ASSOCIATED WITH TYPE 1 VON WILLEBRAND DISEASE.
P18	Candy	Hartshorne	COMPARISON OF POINT OF CARE AND LABORATORY D-DIMER MEASUREMENTS
P19	Patricia	Henne	THE EFFECT OF VON WILLEBRAND FACTOR ON THE INVASIVE POTENTIAL OF BREAST CARCINOMA CELL LINES
P20	Rob	Jones	THE EFFECTS OF RIVAROXABAN ON SPECIALIST COAGULATION TESTS
P21	Dianne	Kitchen	THE FIRST YEAR OF THE POINT OF CARE D-DIMER EQA PROGRAMME, INCLUDING ASSESSMENT OF TESTING AND POST ANALYTICAL INTERPRETATION OF RESULTS
P22	Cynthia	Lessard	EVALUATION OF THE POINT-OF-CARE XPRECIA STRIDE COAGULATION ANALYZER* FOR PT/INR FOR WARFARIN MONITORING
P23	Anna	Lowe	THE EFFECTS OF APIXABAN ON SPECIALIST COAGULATION TESTS
P24	Fraser	McCrae	ROLE OF FIBRINOGEN γ' IN AAA AND THE FUNCTIONAL EFFECTS OF FIBRINOGEN Γ' LEVELS ON CLOT STRUCTURE
P25	Joanne	Mitchell	POLYPHOSPHATE AUGMENTS THE PLASMINOGEN ACTIVATOR FUNCTION OF FACTOR XIa AND CO-LOCALISE ON PLATELET-BOUND FIBRIN
P26	Joanne	Mitchell	DEFECTIVE α 2ANTIPLASMIN CROSS-LINKING AND THROMBUS STABILITY IN A CASE OF ACQUIRED FXIII DEFICIENCY
P27	Ahmad	Mufti	SINGLE NUCLEOTIDE VARIANTS C.2365A>G AND C.2385T>C ARE ASSOCIATED WITH INCREASED VWF PLASMA LEVELS AND VWF:FVIII BINDING
P28	Shelene	Munroe-Peart	NEW POINT OF CARE TESTING (POCT) INR EQA ONE STEP TESTING PROCESS FOR COAGUCHEK XS, XS PLUS AND XS PRO USERS
P29	M. Alexandra L	Santos	OUT OF THE LAB AND INTO THE COMMUNITY: NEW POINT-OF-CARE PT/INR COAGULATION ANALYZER PROVIDING PATIENT BENEFITS FROM COMPLIANCE TO CONVENIENCE
P30	Susan	Shapiro	DUTY OF CANDOUR APPLIED TO HOSPITAL ACQUIRED THROMBOSIS
P31	Elmoamly	Shereef	BLEEDING INCIDENCE AND PHENOTYPE IN HAEMOPHILIA A CARRIERS AND HAEMOSTATIC MEASURES USED.
P32	Lisa	Woodhouse	OUTCOMES IN PATIENTS WITH ISCHAEMIC STROKE OR TRANSIENT ISCHAEMIC ATTACK WHO WITH OR WITHOUT NEW ATRIAL FIBRILLATION: DATA FROM THE 'TRIPLE ANTIPLATELETS FOR REDUCING DEPENDENCY AFTER ISCHAEMIC STROKE' (TARDIS) TRIAL